<DOC>
	<DOCNO>NCT01306110</DOCNO>
	<brief_summary>The aim study evaluate liver fibrosis use FibroScan biochemical marker patient diabetes .</brief_summary>
	<brief_title>Screening Liver Fibrosis Using Non-invasive Methods Patients With Diabetes . A Prospective Study</brief_title>
	<detailed_description>Patients diabetes risk nonalcoholic fatty liver disease ( NAFLD ) lead advanced fibrosis , cirrhosis , liver cancer . However , liver fibrosis screen large population need non-invasive method . Recently , FibroScan show good method diagnosis advance fibrosis NAFLD patient . We examine efficacy screen strategy noninvasive fibrosis biomarker ( FibroTest ) transient elastography ( FibroScan ) patient diabetes .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Male female subject More 18 year age Patients Diabetes Written informed consent Patients refuse participate study provide write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Liver fibrosis</keyword>
	<keyword>diabetes</keyword>
	<keyword>Fibroscan</keyword>
	<keyword>Fibrotest</keyword>
	<keyword>noninvasive fibrosis biomarkers</keyword>
</DOC>